Identification strategy planning support for future disruptive policy trends for orphan drugs

Pharma production

Our client wanted to identify key disruptive trends impacting the HTA, pricing and market access environment for orphan drugs across a range of EU and emerging markets to identify key learnings for internal stakeholders, including senior management.

CRA conducted a landscape assessment across EU and other emerging markets to identify disruptive P&MA trends for orphan drugs. Trends were validated with internal experts and categorised under a comprehensive framework. For each trend CRA performed an impact assessment based on timing and magnitude of impact, leading to a set of prioritised trends across markets. CRA established immediate implications for prioritised trends across the client portfolio and product lifecycles, while future trends were subject to a metric dashboard to identify trigger points for action.

CRA provided a comprehensive EU and emerging markets horizon scanning report with prioritized trends across markets, evidence of impact and implications for the client. CRA facilitated workshops with senior management and regional stakeholders to help them better understand the changing HTA and P&MA environment for rare diseases.